Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

670306.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008 is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
(Date:3/5/2015)... e2b teknologies , a premier Sage ... Ohio, today announced a leading independent multi-specialty physician group ... to the latest version of Sage 100 ERP ... its kind in the region, the organization has an ... efficiency and data accessibility are paramount to their ongoing ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2
... Md., Feb. 15, 2011 United Therapeutics Corporation (Nasdaq: ... for the fourth quarter and year ended December 31, 2010. ... by the growth in our revenues," remarked Martine Rothblatt, ... addition, we are pleased to announce that we expect ...
... Reportlinker.com announces that a new market research report ... Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers ... http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html ... types covered in this report are set to ...
... is available in French . Scientists have ... two paintings by Vincent van Gogh and other artists of ... to understanding how to stop the bright yellow colours of ... brown shade, and fading over time. In the meantime, the ...
Cached Biology Technology:United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 2United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 3United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 4United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 5United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 6United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 7United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 8United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 9Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients 2X-rays show why van Gogh paintings lose their shine 2X-rays show why van Gogh paintings lose their shine 3X-rays show why van Gogh paintings lose their shine 4
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
(Date:2/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND ... new groundbreaking payment method. Payment accounts may be selected ... be accessed if both the speech (the word associated ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... are essential in the fight against breast cancer. ... system for investigation of physiological and pathological processes ... that occurs during puberty and the alveogenesis processes ... in many tissues during embryogenesis and are also ...
... in a wide variety of cells and tissues, including ... can enter the cytoplasm from the extracellular environment or ... enzymes, other signaling molecules, transcription factors, and cytoskeletal components. ... "Calcium Signaling" explores the channels and pumps that transport ...
... For one species of seabird in the Galpagos, the child abuse ... The new study of Nazca boobies by Wake Forest University ... who are abused when they are young often grow up to ... the ornithology journal, The Auk . "We were ...
Cached Biology News:Child abuse in birds: Study documents 'cycle of violence' in nature 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
Biology Products: